Other Transaction Agreement HR00112590241
Award Date 8/14/25
Potential Completion Date 8/14/26
Potential Value $1.8M
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed
Major Defense Program
Not listed Pricing Type
Other
Place of Performance
Baltimore, MD 21201, USA
Solicitation Procedures
Broad Agency Announcement
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a modification to a federal contract awarded by the Office of the Secretary of Defense to Cerus Corporation, a biomedical products company, for the LYOPHILIZED PATHOGEN REDUCED CRYOPRECIPITATE (LYO-CRYO) MANUFACTURING ADVANCEMENT PROJECT. The contract, which has a ceiling value of $24,967,786.00, is an Other Transaction Agreement with no set-aside designation. The contract supports continued development of the company's INTERCEPT Blood System, a technology that uses riboflavin and...
- This is a Small Business Innovative Research (SBIR) Phase I contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Autonomous Healthcare Inc., a for-profit Subchapter S corporation. The $224,459 Firm Fixed Price contract is for the development of an "Automated System for Hemorrhage Control and Resuscitation at Point of Injury", which aligns with DARPA's mission to provide game-changing capabilities to warfighters. The original solicitation was a Broad Agency...
- This is a $3,902,011.00 Firm Fixed Price contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Boundless Science Inc., a small business located in Durham, North Carolina. The contract is for the development of a "Novel Blood Oxygenation Device to Save Warriors on the Battlefield" under the Small Business Innovation Research (SBIR) Program Phase II. The contract has a period of performance ending on August 2, 2026. This award is designated as a Total Small...
- This is a $10,185,361.55 federal contract award to the Medical Technology Enterprise Consortium (MTEC), a nonprofit organization that serves as a medical technology accelerator for the Department of Defense. The contract is for a prototype project titled "Development of an Oxygen Carrier for Use in Hemorrhagic Shock Resuscitation" under the Multi-Topic Request for Project Proposals (MTEC 17-08 Multi-Topic) solicitation. The contract is awarded by the Defense Health Agency, a defense...
- The U.S. Defense Health Agency (DHA) awarded a $250,000.00 Small Business Innovation Research (SBIR) Phase I contract to Gand Inc., a for-profit medical research and development company based in Miami Beach, Florida. The contract is for a project titled "Manufactured Universal Whole Blood-Like Fluid" and is set aside for total small businesses. This award is part of the DHA's SBIR program, which funds feasibility studies, further research and development, and commercialization of...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Xilis Inc., a for-profit manufacturing organization. The contract is for the development of tissue-derived droplet micro-organospheres as models for high-throughput testing of pathogens, with a total potential value of $224,658.00. The contract has a firm fixed price pricing type and a completion date of August 31, 2021. The original solicitation was a Broad...
- This federal contract award, with a ceiling value of $149,927.17, was issued by the U.S. Medical Command (MEDCOM) to Cytosorbents Medical Inc., a small business manufacturer of medical devices and technologies. The contract is for a SBIR Phase I research project under the Defense Health Program (DHP), with the goal of developing an extracorporeal cytokine adsorber to treat septic shock. As a small business set-aside, Cytosorbents is the prime contractor responsible for conducting the research to...
- This is a $6,456,388.02 definitive, firm-fixed-price contract awarded by the Office of the Assistant Secretary for Preparedness and Response to the University of Cincinnati to develop and validate the use of biotin as an in vivo labeling agent for red blood cells, replacing the current FDA-approved chromium 51 technology. The contract aims to support regulatory studies for the approval of novel or modified blood products in the United States. Major subcontractors include the Dana-Farber Cancer...
- <p>The U.S. government has awarded a $12,534,579.00 firm fixed-price definitive contract to Hemoglobin Oxygen Therapeutics LLC, a for-profit limited liability company, for "Canine Oxygen Carrier Manufacturing Restoration and Regulatory Activities." The contract, which does not have a set-aside designation, is being funded by the Defense Health Agency, a defense agency. The work is to be performed in Souderton, Pennsylvania, with a completion date of May 31, 2029.</p>
- This is a federal contract award from the National Heart Lung and Blood Institute, a civilian agency, to New Health Sciences, Inc. (doing business as Hemanext Inc.), a small business manufacturer. The $1,660,011.00 contract is for the development of a novel, low-cost blood storage system that will deliver higher quality red blood cells, thereby reducing the harmful consequences of transfusion therapy. This contract is part of the SBIR (Small Business Innovation Research) Phase I program, under...